Loncastuximab Tesirine: Breaking Down the CD19 Antibody-Drug Conjugate Revolution

Abbv-319: a novel, CD19-GRM antibody-drug conjugate being explored for R/R B-cell malignanciesПодробнее

Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffu...Подробнее

What I Tell My Patients: Faculty Physicians and Nurses Discuss Patient Education About New Treatm...Подробнее

Addressing Challenges in Antibody-Drug Conjugate DevelopmentПодробнее

The Development of a Next Generation Antibody Drug Conjugate ADCПодробнее

The Next Generation Pharmaceuticals - Antibody-drug Conjugates (ADCs)Подробнее

Novel Antibody Drug Conjugates in Development for Lymphoid MalignanciesПодробнее

Loncastuximab tesirine: a novel antibody-drug conjugate for DLBCLПодробнее

How Do Antibody-Drug Conjugates ADCs Work?Подробнее

Diffuse Large B-Cell Lymphoma | Oncology Today with Dr Neil Love: Advances in Diffuse Large B-Cel...Подробнее

A View On Antibody-Drug ConjugatesПодробнее

New and future treatments for lymphoma - Prof Andy DaviesПодробнее

Sepax Webinar: Analytical Characterization of Antibody Drug ConjugatesПодробнее

Bio-Techne ReproducibilityПодробнее

Changing Times in DLBCL and Practicalities of Antibody TherapyПодробнее

Drug Discovery: Capital and TimeПодробнее

Context Therapeutics webinar: Claudin 6 x CD3 bispecific antibody data updateПодробнее

Exon structure of CD19 and CD22 mRNA isoforms revealed by long read sequencing - Mukta AsnaniПодробнее